Athanor Capital, LP Incyte Corp Transaction History

Athanor Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$79.87 - $87.53 $369,398 - $404,826	-4,625 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$76.02 - $100.5 $479,002 - $633,250	-6,301 Reduced 57.67%	4,625 $376,000
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $882,165 - $1.07 Million	10,926 New	10,926 $950,000
Q3 2020 Nov 16, 2020	SELL	$85.07 - $109.69 $738,918 - $952,767	-8,686 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$74.18 - $108.93 $644,327 - $946,165	8,686 New	8,686 $903,000
Q1 2020 May 14, 2020	SELL	$63.18 - $85.97 $644,436 - $876,894	-10,200 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$73.04 - $95.72 $233,728 - $306,304	3,200 Added 45.71%	10,200 $891,000
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $509,739 - $605,640	7,000 New	7,000 $520,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.